MOREPEN LAB. LTD

Morepen Laboratories Limited's investor presentation for Q1 FY27 highlighted significant financial achievements, including the highest-ever quarterly revenue of Rs. 825 crore and a 3x year-over-year increase in EBITDA, reaching Rs. 87.72 crore. The presentation emphasized the commercial validation of the Morepen 2.0 strategy, with a focus on operational execution leading to a 15%+ EBITDA margin. The company reported a 111% increase in export revenue and a 394% rise in profit after tax (PAT) to Rs. 56.35 crore. Management noted a transition from commodity APIs to innovation-led manufacturing, aiming for predictable earnings through long-duration customer programs. The presentation also outlined plans for capacity expansion and a commitment to sustainable operations, supporting long-term growth and global partnerships.

The presentation emphasized strong financial performance and strategic growth initiatives.